Citius Oncology (CTOR) Times Interest Earned (2024 - 2026)

Citius Oncology's (CTOR) quarterly Times Interest Earned came in at 37.62 in Q2 2026, up 95.66% quarter-over-quarter from 866.26 in Q1 2026.

Analysis

Citius Oncology (CTOR) Times Interest Earned (2024 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Times Interest Earned for 3 consecutive years, with 37.62 the latest figure, recorded in Q2 2026.

On a quarterly basis, Times Interest Earned changed N/A year-over-year to 37.62 in Q2 2026; TTM through Jun 2026 was 128.56, a N/A change from a year earlier, with the FY2025 full-year figure at 4.37, changed N/A from the prior year.
Times Interest Earned was 37.62 for Q2 2026 at Citius Oncology, up from 866.26 in the prior quarter.
Over five years, Times Interest Earned peaked at 13.61 in Q4 2024 and troughed at 866.26 in Q1 2026.
A 3-year average of 222.86 and a median of 82.26 in 2025 frame the typical range for Times Interest Earned.
The widest YoY moves for Times Interest Earned: up 742.08% in 2025, down 742.08% in 2025.
Over 3 years, Times Interest Earned stood at 13.61 in 2024, then plunged by 742.08% to 114.58 in 2025, then jumped by 67.17% to 37.62 in 2026.
The last three Times Interest Earned figures came in at 37.62 (Q2 2026), 866.26 (Q1 2026), and 114.58 (Q4 2025), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn	5.22
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn	-42.08
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn	117.59
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn	493.00
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn	2.82
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn	-
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn	-
10	Citius Oncology	101.41 Mn	101.41 Mn	1.00 Mn	-37.62

Historic Data

Download Data